Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201062 | 0.81 | ALDH1A1 (0.59) | ALDH1A1SIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL20922739 | 0.79 | SIGMAR1 (0.65) | SIGMAR1MAPTL3MBTL3L3MBTL1 | |
| SCHEMBL17598264 | 0.78 | SMN1; SMN2 (0.61) | ALDH1A1MAPTL3MBTL3L3MBTL1 | |
| SCHEMBL27717752 | 0.76 | SMN1; SMN2 (0.55) | ALDH1A1 | |
| SCHEMBL27717893 | 0.76 | SMN1; SMN2 (0.55) | ALDH1A1 | |
| SCHEMBL27739137 | 0.75 | HTR7 (0.56) | ALDH1A1 | |
| SCHEMBL17549652 | 0.75 | ALDH1A1 (0.73) | ALDH1A1SIGMAR1MAPTL3MBTL3L3MBTL1 | |
| SCHEMBL13089690 | 0.74 | L3MBTL1 (0.54) | L3MBTL3L3MBTL1 | |
| SCHEMBL4236906 | 0.74 | L3MBTL3 (0.61) | MAPTL3MBTL3L3MBTL1 | |
| SCHEMBL20922550 | 0.73 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099761-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | VILLAPHARMA RESEARCH S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | VILLAPHARMA RESEARCH S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| WO-2008068272-A2 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB5, NDUFB7 | ALDH1A1 2506/4885BLM 618/4885SIGMAR1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.